An FAQ for Anatomic Pathology Leaders and Beyond
FDA LDT Rule Compliance is a crucial concern for anatomic pathology labs adapting to new regulations. On October 29, 2024, NovoPath hosted a pivotal session in its Expert Speaker Series: “Cracking the Code: Your Lab and the First 6 Months of the FDA’s LDT Rule.” Moderated by NovoPath CEO Promise Okeke, the event featured Sheila Walcoff, JD, CEO of Goldbug Strategies and a leading FDA policy authority on Laboratory Developed Tests (LDTs), In Vitro Diagnostics (IVDs), and digital health technologies.
Below is a curated list of frequently asked questions (FAQ) raised during the event, along with answers that reflect the latest insights six months into the LDT rule. This FAQ is particularly relevant to anatomic pathology (AP) and molecular labs that must meet new compliance expectations under heightened FDA oversight.
1. Are LDTs Used Before May 6, 2024, Automatically Grandfathered In?
Short Answer: Not necessarily.
Explanation: Some labs assume older LDTs are exempt from new requirements. However, any significant modifications to an existing test—including changes to reagents, software, or the underlying protocol—may prompt the FDA to request additional validation. Labs that diligently document these changes (and can produce organized records) tend to navigate reviews more smoothly.
2. How Does the FDA Define “Automation” in the Context of AP Labs?
Short Answer: It’s broader than you might think.
Explanation: In anatomic pathology, automation doesn’t just refer to robotic instruments or automated staining platforms. It can also include AI-driven image analysis, digital pathology workflows, and computerized tools for tasks like Gleason grading. If software or hardware impacts the clinical interpretation, it’s likely to come under closer scrutiny—especially if labeled as part of an LDT pathway. Having robust digital tools in place to capture these processes can help labs maintain clarity on which activities fall under “automation.”
3. What Are the Key Compliance Obligations if Our Lab Uses Computer-Assisted Methods?
Short Answer: You must ensure transparency and traceability.
Explanation: AP labs that incorporate automated or computer-assisted steps—like algorithmic scoring—should be able to demonstrate how each step in the testing process is verified. This includes documenting software version changes, validation data, and any risk assessments performed when introducing new technologies or updates. Consistency in data capture and reporting ensures labs can respond promptly to FDA inquiries.
4. We Use Third-Party Components Labeled “RUO.” What Now?
Short Answer: Document, validate, and monitor closely.
Explanation: Research Use Only (RUO) reagents and software often end up in clinical workflows out of necessity. Under the new rule, the FDA may scrutinize labs that rely on RUO materials for patient-facing diagnostics. It’s essential to demonstrate thorough analytical validation and to maintain clear usage records, showing how you ensure safety and effectiveness despite the RUO label.
5. Our Lab Performs Manual H&E Staining but Uses Automation Elsewhere. Is That an Issue?
Short Answer: Potentially, if the automated steps are integral to clinical decision-making.
Explanation: The FDA focuses on test components that significantly influence clinical results. Manual H&E staining alone may not raise regulatory red flags; however, subsequent automated or AI-based analysis could. Labs should maintain clear segmentations between manual and automated processes so regulators see exactly where each method applies.
6. Are Labs Subject to FDA Compliance If They Modify IVD Kits or Reagents Only Slightly?
Short Answer: Even small modifications can trigger oversight.
Explanation: Many IVD kits are approved or cleared with specific instructions and sample types. Deviations—such as using a different specimen matrix—might classify the test as an LDT in the FDA’s eyes. Thorough documentation of each change, supported by validation data, can help mitigate compliance risks.
7. We Use Instruments and Reagents Not Labeled for IVD Use. What Does That Mean for Us?
Short Answer: Elevated scrutiny and a need for thorough risk assessment.
Explanation: In high-complexity labs, it’s common to push the envelope with advanced instruments not specifically labeled as IVD. If these tools play a direct role in patient diagnosis, the FDA expects documented performance data. A cohesive approach to tracking performance metrics ensures labs can easily reference this information during audits or inspections.
8. How Does the LDT Rule Impact Labs Within Integrated Health Systems?
Short Answer: Collaborative oversight is key.
Explanation: Integrated health system labs often develop specialized LDTs to address unmet needs. The FDA may question whether these tests remain “within-system” or if they’re effectively offered more broadly. Coordinated policies across the entire health system—particularly when sharing data or expanding testing sites—can demonstrate compliance readiness.
9. When Can We Expect FDA Enforcement, and How Should We Prepare?
Short Answer: Timelines are fluid, but preparedness is essential.
Explanation: While the FDA has signaled a phased enforcement approach, labs can’t assume indefinite leeway. Surprise inspections or focused inquiries can still occur. Keeping standardized records, ensuring version control, and aligning your testing workflow with current guidance position you to handle regulatory scrutiny without significant disruption.
Practical Steps to Stay Ahead
1. Stay Informed
Regulations can shift rapidly. Keep up with news from industry groups and regulatory advisories, and watch for opportunities (like NovoPath’s Expert Speaker Series) to learn from those on the front lines.
2. Refine Your Documentation
A well-structured audit trail of how, when, and why you modify tests is invaluable. Digital solutions that consolidate these details can make your life much easier.
3. Seek Specialized Expertise
If you’re concerned about litigation or policy hurdles, consider contacting Goldbug Strategies for deeper FDA regulatory insights tailored to your specific test portfolio.
4. Evaluate Your Lab Information System
Many labs discover that a modern, cloud-based LIS can alleviate the pain points of regulatory documentation. Streamlined data capture and version control often prove critical in addressing FDA queries efficiently.
5. Collaborate Internally
From lab directors to IT staff, engage all stakeholders. An integrated approach ensures everyone understands new compliance tasks and shares responsibility for sustaining best practices.
Next Steps for Your Lab
As the FDA’s LDT rule continues to shape the regulatory environment, labs must balance innovation with careful adherence to new standards. Whether you’re re-validating older tests, integrating AI tools, or expanding test offerings, robust operational structures—and the right technology—can keep you on track.
Connect with Goldbug Strategies for litigation support or regulatory consultations.
NovoPath provides a comprehensive SaaS solution designed to simplify complex workflows, centralize documentation, and help labs adapt to evolving demands.
Contact NovoPath to discover how our platform can streamline your lab’s operations and keep you aligned with FDA requirements—without forcing you to sacrifice efficiency or innovation. We look forward to supporting your lab’s journey toward regulatory confidence and operational excellence.